Pain Management · OpioidRegulatory Approvalregulatorymid-term

FDA Accepts Supplement for XTAMPZA ER by Collegium Pharma

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Collegium Pharma6 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/28/2026, 6:32:53 PM

Assessment confidence: 66% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of the supplemental application for XTAMPZA ER is a significant regulatory milestone that could strengthen Collegium Pharma's competitive position in the opioid pain management market. This development necessitates close monitoring of market dynamics and potential responses from competitors. Regulatory context from FDA (FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose) supports the near-term read. Assessment grounded in 9 ranked evidence items (5 high-relevance).

Strategic Assessment

Portfolio teams should assess the potential market impact and competitive response from other opioid manufacturers. The strongest clinical anchor is Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain (ClinicalTrials.gov), sub-indication match (pain). In pain, 3 regulatory and 2 competitive items passed relevance filtering for Collegium Pharma.

Competitive Pressure

The most relevant competitive pressure comes from FDA Approval for Oxycodone Hydrochloride by Novel Labs (Humanexa Signals) — sub-indication match (pain). Secondary pressure from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need. This acceptance may enhance Collegium Pharma's position in the pain management market, particularly against other opioid formulations.

Regulatory Outlook

Regulatory risk is concentrated around FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose (FDA). Sub-indication match (pain). The acceptance of the supplemental application indicates a positive regulatory trajectory, but further developments in the approval process will need to be monitored closely.

Key Risks

Elevated medium regulatory exposure for Collegium Pharma could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The approval could lead to increased market share for Collegium Pharma, impacting revenue streams and competitive positioning against other opioid formulations.
Portfolio teams should assess the potential market impact and competitive response from other opioid manufacturers.

What Would Change This Assessment

This becomes more urgent if Monitor for further updates on the approval timeline and any competitive reactions from other pain management therapies.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose
FDAhigh relevance
Sub-indication match (pain)
FDA document
View source
FDA AP — XTAMPZA ER (SUPPL)
FDAmedium relevance
Entity match (xtampza er)
FDA document
View source
FDA AP — XTAMPZA ER (SUPPL)
FDAmedium relevance
Entity match (xtampza er)
FDA document
View source
Report on the State of Pharmaceutical Quality
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Investigating the Analgesic Potential of (2R,6R)-HNK in Acute Pain in Healthy Volunteers
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Effect of Nociception Level Monitoring During Remimazolam-based Total Intravenous Anesthesia on Intraoperative Opioid Requirements and Postoperative Pain
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Evaluation of the Japet.W+ Medical Device for Low Back Pain Management
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Effects of Music Therapy in Chronic Neck Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

FDA Approval for Oxycodone Hydrochloride by Novel Labs
Humanexa Signalsmedium relevance
Sub-indication match (pain)
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizermedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalslow relevance
Sponsor/company relevance (Roche)
FDA Accepts Supplemental BLA for OCREVUS ZUNOVO by Genentech
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Immunotherapeutic landscape of amyotrophic lateral sclerosis: A bibliometric analysis of research trends, translational priorities, and collaboration networks (2006-2025).
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Nanomedicine-based cancer immunotherapy: translational barriers, mechanistic strategies, and future perspectives.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Immunogenicity and safety of a 2 + 1 schedule of the DTaP-IPV-HB-Hib hexavalent combination vaccine in preterm infants in Spain.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
The Effect of Moxibustion at the Dazhui Point on Hypothermia and Maternal Comfort During Cesarean Delivery: A Randomized Controlled Trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Collegium Pharma
XTAMPZA ER
other opioid manufacturers

Commercial impact

medium

The approval could lead to increased market share for Collegium Pharma, impacting revenue streams and competitive positioning against other opioid formulations.

Regulatory impact

medium

The acceptance of the supplemental application indicates a positive regulatory trajectory, but further developments in the approval process will need to be monitored closely.

What to watch

Monitor for further updates on the approval timeline and any competitive reactions from other pain management therapies.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.